Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,016 across all filing types
Latest filing 2026-01-15 Director's Dealing
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of share transactions by Persons Discharging Managerial Responsibilities (PDMRs), specifically David Redfern and Victoria Whyte of GSK plc. The content follows the standard regulatory format for reporting insider dealings (PDMR transactions) under the Market Abuse Regulation (MAR). This falls directly under the 'Director's Dealing' category.
2026-01-15 English
6-K Filing
Regulatory Filings
2026-01-15 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a standard regulatory notification regarding transactions in shares by Persons Discharging Managerial Responsibilities (PDMRs). It explicitly lists the names, positions, and transaction details (acquisition of shares via dividend reinvestment) for multiple executives at GSK plc. This aligns perfectly with the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2026-01-13 English
6-K Filing
Regulatory Filings
2026-01-13 English
EC approval of Shingrix PFS
Regulatory Filings Classification · 95% confidence The document is a press release from GSK plc announcing the European Commission's approval of a new prefilled syringe presentation for their Shingrix vaccine. It provides detailed product information, background on shingles, and company contact details. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is informational and promotional in nature, typical of a Regulatory News Service (RNS) announcement. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. The length (9004 characters) and content confirm it is a regulatory announcement rather than a full report or financial filing.
2026-01-07 English
Positive phase 3 data for GSK's bepirovirsen
Regulatory Filings Classification · 95% confidence The document is a press release from GSK dated 7 January 2026 announcing positive results from two phase III clinical trials (B-Well 1 and B-Well 2) for a drug candidate, bepirovirsen, for chronic hepatitis B. It includes detailed clinical trial results, scientific context, and future regulatory filing plans. The document is not a financial report, earnings release, or regulatory filing but rather a corporate announcement of clinical trial outcomes. It does not contain financial statements or management discussion of financial results. It is a typical example of a Regulatory Filing (RNS) as it is a general regulatory announcement and corporate news release distributed via the Regulatory News Service (RNS) of the London Stock Exchange. The document length (9742 characters) and content confirm it is not a brief announcement of a report publication (RPA) nor a full annual or interim report. Therefore, the best classification is Regulatory Filings (RNS).
2026-01-07 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.